Vivo Bio Tech (511509)

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I have always said it is far better to buy a wonderful company at a fair price than a fair company at a wonderful price. Vivo Bio Tech tests that discipline. At ₹37.69, the market cap is only ₹56 crore, the P/E is 13.27, and the P/B is 1.34 against a book value of ₹28.16. That sounds reasonable, but I must ask what returns the business generates. ROE of 7.82% and ROCE of 9.04% are simply not attractive; a durable compounder normally earns far more on capital. Still, the reported momentum is real: sales grew 10.65%, profits jumped 52.44%, and the PEG is 0.42. If that profit growth can be sustained, the valuation is not expensive. The Piotroski F-Score of 7/9 also gives me some comfort that the fundamentals are not deteriorating. But I am uncomfortable with what is missing: debt-to-equity is not available, promoter holding is not disclosed, and the latest quarter's ₹14 crore in sales produced only ₹1 crore of net profit, a thin margin. There is no dividend, so all my returns depend on reinvestment in a business earning less than 10% on capital. This looks like a small fast grower, not a high-quality moat. A ₹56 crore microcap can swing wildly; the 52-week range of ₹20.35 to ₹43.35 shows that. I would keep any position small, insist on verifying the balance sheet, and wait for evidence that the 52% profit growth is not a one-off.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer